Pharmala Biotech Holdings IncGrey Market:MDXXFView on Canadian Exchange
- LAST PRICE0.1412
- TODAY'S CHANGE (%)0.0070 (5.2161%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.1332 / 0.1342
- Day Range
- 52 Week Range
- Volume3,150
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | MDXXF |
|---|---|---|
| 09:39 ET | 1850 | 0.1332 |
| 10:55 ET | 1300 | 0.1412 |
May 3, 2024
PharmAla Launches Prescriber's Portal for Medical Professionals Focused on MDMA Therapy, from 11:00AM ET on Friday May 03, 2024 by Dow Jones
11:00AM ET on Friday May 03, 2024 by Dow Jones
Apr 23, 2024
PharmAla Biotech Advances Global MDMA Production and Research, from 7:02PM ET on Tuesday Apr 23, 2024 by Dow Jones
7:02PM ET on Tuesday Apr 23, 2024 by Dow Jones
Apr 19, 2024
PharmAla Closes Private Placement and Concurrent Debt Settlement, from 8:35AM ET on Friday Apr 19, 2024 by Dow Jones
8:35AM ET on Friday Apr 19, 2024 by Dow JonesPress Release: PharmAla Closes Private Placement and Concurrent Debt Settlement, from 8:35AM ET on Friday Apr 19, 2024 by Dow Jones
8:35AM ET on Friday Apr 19, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Pharmala Biotech Holdings Inc | 17.7M | 0.0x | --- |
Company Information
PharmAla Biotech Holdings Inc. is a Canada-based biotechnology company. The Company is focused on the development, manufacture and sales of methylenedioxy methamphetamine (MDMA) and methylenedioxy phenethylamines (MDXX) class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The Company has three primary business lines: the manufacture of MDMA and MDXX class molecules for sale to clinical researchers in both the commercial and academic sphere, the research and development of novel MDXX class compounds which offer unique benefits above and beyond known substances, and the development of novel delivery mechanisms for MDMA and MDXX class compounds. Its research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. It works with laboratories across Canada to develop novel processes for the supply of LaNeo MDMA and other MDXX substances.
Contact Information
- Headquarters
- 82 Richmond St. EastVANCOUVER, BC, Canada M5C 1P1
- Phone
- ---
- Fax
- ---
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $17.7M |
|---|---|
Revenue (TTM) | $1.3M |
Shares Outstanding | 91.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.01 |
Book Value | $0.02 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | 13.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -47.22% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
